Article
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Blood - 21 Nov 2013
Zimmerman Eric I, Turner David C, Buaboonnam Jassada, Hu Shuiying, Orwick Shelley, Roberts Michael S, Janke Laura J, Ramachandran Abhijit, Stewart Clinton F, Inaba Hiroto, Baker Sharyn D
Abstract excerpt
FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are observed in FLT3-ITD-positive patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691. Using biochemical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.